Search Results

STELLAR-311: Zanzalintinib Versus Everolimus in pNET and epNET << Back STELLAR-311: Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Cancers IDENTIFIER ( ClinicalTrials.gov ) : NCT06943755 DRUG/TREATMENT : Zanzalintinib and Everolimus PHASE : 2/3 STATUS : Recruiting SPONSOR : Exelixis Zanza-Phase3 Presentation Slides .pdf Download PDF • 226KB DESCRIPTION: A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors. The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors. For more information on eligibility criteria, trial locations, study details, etc., go to STELLAR-311 Clinical Trial (Exelixis) and/or ClinicalTrials.gov to view this trial here. CONTACT: Exelixis Clinical Trials, STELLAR-311 Clinical Trial (Exelixis) EMAIL: druginfo@exelixis.com PHONE: 1-888-EXELIXIS (888-393-5494) This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information. OTHER HELPFUL RESOURCES: This Exelixis study site STELLAR-311 Clinical Trial (Exelixis) includes a toll-free medical information hotline, information on the study and eligibility criteria and study sites *Please note, Zanzalintinib is an investigational agent that is not approved for any use and is the subject of ongoing clinical trials.

Lu-177 DOTATATE vs Everolimus in Lung NETs << Back Randomized Phase II Trial of Lutetium Lu-177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors DRUG/TREATMENT: LUTETIUM LU-177 DOTATATE (PRRT) + (EVEROLIMUS) CLINICALTRIALS.GOV IDENTIFIER: NCT04665739 PHASE: 2 STATUS: Recruiting SPONSOR: National Cancer Institute (NCI) Dr. Suki Padda Discusses Lu177 Dotatate in Lung NETs Dr. Heloisa Soares Discusses Lu-177 Dotatate in Lung NETs DESCRIPTION: This phase II trial studies the effect of lutetium Lu-177 dotatate compared to the usual treatment (everolimus) in treating patients with somatostatin receptor positive bronchial neuroendocrine tumors that have spread to other places in the body (advanced). Radioactive drugs, such as lutetium Lu-177 dotatate, may carry radiation directly to tumor cells and may reduce harm to normal cells. Lutetium Lu-177 dotatate may be more effective than everolimus in shrinking or stabilizing advanced bronchial neuroendocrine tumors. For more information on eligibility criteria, trial locations, study details, etc. go to ClinicalTrials.gov to view this trial here. PRINCIPAL INVESTIGATORS: Thomas A. Hope, MD, UCSF Sukhmani K. Padda, MD, Cedars Sinai Medical Center, Los Angeles, California CONTACT: This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information.

Lu-177 DOTATATE + Sunitinib in PNETs << Back Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors IDENTIFIER ( ClinicalTrials.gov ) : NCT05687123 DRUG/TREATMENT : Lu177 dotatate + sunitinib study PHASE : 1 STATUS : Recruiting SPONSOR : National Cancer Institute (NCI) DESCRIPTION: This phase I trial tests the safety, side effects, and dosimetry of sunitinib malate in combination with lutetium Lu 177 dotatate in treating patients with pancreatic neuroendocrine tumors. Sunitinib malate is in a class of medications called kinase inhibitors and a form of targeted therapy that blocks the action of abnormal proteins called VEGFRs that signal tumor cells to multiply. This helps stop or slow the spread of tumor cells. Radioactive drugs, such as lutetium Lu 177 dotatate, may carry radiation directly to tumor cells and not harm normal cells. It is also a form of targeted therapy because it works by attaching itself to specific molecules (receptors) on the surface of tumor cells, known as somatostatin receptors, so that radiation can be delivered directly to the tumor cells and kill them. Giving sunitinib malate and lutetium Lu 177 dotatate in combination may be safer and more effective in treating pancreatic neuroendocrine tumors than giving either drug alone. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT : Principal Investigator: Nikolaos Trikalinos,Yale University Cancer Center LAO RELATED RESOURCES Clinical Trials Using Lutetium Lu 177 Dotatate - NCI

<< Go back to the Podcast page EPISODE 26: WHAT TO KNOW ABOUT LUNG NETS Download the transcript here: LACNETS Podcast Episode 26_Lung NETs .pdf Download PDF • 208KB ABOUT THIS EPISODE What are lung NETs? What is DIPNECH? How is lung NET similar or different from lung cancer? Dr. Vineeth Sukrithan from Ohio State University Comprehensive Cancer Center gives a comprehensive overview of lung NET and DIPNECH, including the work-up and treatment options. He also discusses open clinical trials and exciting advances in lung NET research on the horizon. MEET DR. VINEETH K. SUKRITHAN Dr. Vineeth Sukrithan is a medical oncologist who specializes in the study and treatment of neuroendocrine cancer, thyroid cancer and adrenocortical cancer. He utilizes traditional chemotherapy, molecularly targeted oral medications, novel immunotherapy and peptide-receptor radiotherapies in the treatment of these unique cancers. As a comprehensive cancer center, the OSUCCC – James has unrivaled experience and expertise in the treatment of neuroendocrine, thyroid and adrenal tumors. Their world-renowned faculty are leaders in the study and treatments of these rare cancers, and as such, they are able to provide their patients with options beyond standard therapies that may not be available anywhere else. The strong focus on translational research at The James means that the treatment breakthroughs of tomorrow are being discovered in their laboratories today. Dr. Sukrithan is part of a tight-knit team of surgical oncologists, radiation oncologists and interventional radiologists who work together to provide cutting-edge care for our patients with neuroendocrine tumors. In addition to his clinical work, Dr. Sukrithan is a member of the Translational Therapeutics Program at the OSUCCC – James and the co-director of the Adrenal Tumor Clinic. He was recently selected to lead an externally funded effort through the International Thyroid Oncology Group to operationalize a multi-institutional registry database for patients with medullary thyroid cancer. Dr. Sukrithan also serves as an assistant professor in the Division of Medical Oncology at The Ohio State University and has completed postdoctoral fellowships in clinical research at Johns Hopkins University. His research has been published in numerous peer-reviewed journals, including Cancer Research, American Journal of Clinical Oncology and Clinical Lung Cancer. As every individual’s cancer is molecularly unique in countless ways, Dr. Sukrithan believes in tailoring therapies to the individual with the precision made available through cutting-edge scientific research. He feels it is a privilege to make a difference in the lives of patients as we work together to achieve a cancer-free world. TOP 10 QUESTIONS What are lung NETs? Where are they located? How are lung NETs found? What are the symptoms of a lung NET? How is lung NETs different (or similar) to what is commonly referred to as “lung cancer”? How is it different or similar to DIPNECH? Do all lung NET patients have DIPNECH and do all DIPNECH patients have lung NET? How is lung NET similar or different from other types of NETs? What makes it unique? What types of labs, scans, or testing is done to determine if someone has a lung NET and DIPNECH? What is the best type of scan for lung NETs? How do you decide if the lung NET can be surgically removed? What type of surgeon would make that determination and when in their patient journey might they see a surgeon? How are lung NETs treated medically (or nonsurgically)? How are the treatments different from other NETs? How are treatments sequenced? How are lung NETs monitored? What types of blood work, tests and scans should be done and how often should they be done? What advances in the field or clinical trials should we be aware of? What new advances or treatments in the pipeline for lung NETs are you most excited about? RESOURCES Lung NET Clinical Trials mentioned in this episode: PRRT TRIAL for lung NET: phase 2 trial studying the effect of lutetium Lu 177 dotatate (PRRT) compared to the usual treatment (everolimus) in treating patients with somatostatin receptor positive ADVANCED bronchial Neuroendocrine Tumors CABINET: Cabozantinib in Advanced pNET and Carcinoid Tumors A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms in Clinical Cancer Research Lung NET Resources: LACNETS Lung NET Resources Lung NET Clinical Trials in the LACNETS Clinical Trials Guide WATCH: NET Patient Dorinda shares her NET Journey "Focus on Lung Carcinoid Tumors" with Dr. Robert Ramirez "Update on Lung NETs" with Dr. Sukhmani K. Padda DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

< Back to the upcoming events page Registration is closed. Please contact us at events@ncf.net to be added to the waitlist. ABOUT The Neuroendocrine Cancer Foundation is hosting an in-person Neuroendocrine Cancer Educational Event for patients and caregivers in Santa Monica, California on Saturday, May 17th, from 3:45 -7:30 PM. Hear four presentations from neuroendocrine cancer experts. Engage in two Q&A sessions. Listen to a patient story. Learn about liver-directed therapy, systemic therapy, PRRT, and clinical trials. Network with other patients and caregivers. A light dinner will be served. There is no cost to attend. This event is made possible by the generosity of donors and sponsors. Special thanks to our host, Dr. Alexandra Gangi (Cedar-Sinai Medical Center). This event will not be broadcast or recorded. Note: The Neuroendocrine Cancer Foundation was formerly known as LACNETS. Read the full announcement here >>> LOCATION Sandbourne Santa Monica 1740 Ocean Avenue Santa Monica, CA 90401 THANKS TO OUR SUPPORTERS AGENDA Time Topic Speaker 3:45 - 4:15 PM Check-in 4:15 - 4:25 PM Welcome & Introductions Neuroendocrine Cancer Foundation Team 4:25 - 4:30 PM Patient Story 4:30 - 4:45 PM Liver-Directed Therapy: Understanding Minimally Invasive Options to Treat Liver Tumors Gabriel Lipshutz, MD, Interventional Radiologist, Cedars-Sinai 4:45 - 5 PM Systemic Therapy for NETs: Medical Options for Metastatic Tumors J. Randolph Hecht, MD, UCLA 5 - 5:45 PM Q&A with Expert Panel Callisia Clarke, MD, Julie Hallet, MD, Gabriel Lipshutz, MD, Randolph Hecht, MD; Moderated by Alexandra Gangi, MD 5:45 - 6:30 PM Break & Dinner 6:30 - 6:45 PM PRRT: Current & New Trends Thorvardur Halfdanarson, MD, Medical Oncologist, Mayo Clinic 6:45 - 7:00 PM Clinical Trials: The Latest & Greatest Heloisa Soares, MD, Huntsman Cancer Institute 7:00 - 7:30 PM Q&A with Expert Panel Thorvardur Halfdanarson, MD, Heloisa Soares, MD, Alexandra Gangi, MD; Moderated by Andrew Hendifar, MD 7:30 PM Closing Neuroendocrine Cancer Foundation Team This agenda is subject to change. Please check this page for the most updated agenda. ABOUT OUR SPEAKERS Callisia Clarke, MD, MS, FACS, FSSO Chief of MCW Surgery Medical College of Wisconsin Panelist Dr. Clarke is Chief of Surgical Oncology and Associate Professor of Surgery at the Medical College of Wisconsin with a focus on tumors of the upper gastrointestinal tract, sarcomas, melanomas and regional therapies for advanced malignancies. She specializes in hepato-pancreatic-biliary malignancies, primary and metastatic neuroendocrine tumors, melanoma and sarcoma. Her research efforts focus on personalized cancer care and targeted approaches in pancreatic neuroendocrine tumors. Dr. Clarke also serves on the Executive Committee of the Association for Academic Surgery and is the Chair of the North American Neuroendocrine Tumor Society (NANETS) Mentoring and Early Career Development Committee. President Biden recently announced she will be appointed as a Member of the National Cancer Advisory Board. Dr. Clarke will play a key role in guiding the Director of the National Cancer Institute in setting the course for the national cancer research program and help advance breakthroughs to prevent, detect, and treat diseases like cancer. Alexandra Gangi, MD Surgical Oncologist Cedars-Sinai Medical Center Moderator/Panelist Dr. Alexandra Gangi is a board-certified surgical oncologist at Cedars-Sinai Medical Center in Los Angeles. Dr. Gangi completed a general surgical residency at Cedars-Sinai and completed her surgical oncology fellowship at the H. Lee Moffitt Cancer Center in Tampa, Florida. She currently serves as the director of the Gastrointestinal Tumor and Cancer Regional Therapies Programs with specialization in Pancreatic and GI Neuroendocrine tumors, Metastatic colorectal cancer, and Peritoneal Surface Malignancies. Her research focuses on understanding GEPNET heterogeneity between and within tumors subtypes and mechanisms of chemotherapy induced liver injury. Thorvardur Halfdanarson, MD Medical Oncologist Mayo Clinic Speaker/Panelist Thor R. Halfdanarson, M.D., is a medical oncologist and Professor of Oncology at Mayo Clinic who specializes in the management of patients with neuroendocrine neoplasms, gastrointestinal malignancies and unknown primary malignancies. His specific research interests include the epidemiology, risk factors and treatment of neuroendocrine tumors and neuroendocrine carcinoma and improving outcomes for pancreatic adenocarcinoma and rare types of pancreatic tumors. He is a principal investigator and co-investigator for multiple industry-sponsored and cooperative group clinical trials. Dr. Halfdanarson holds several leadership positions within Mayo Clinic Comprehensive Cancer Center. He is chair of the Hepato-Pancreatico-Biliary Cancer Disease Group and co-chair of the Pancreatic/Neuroendocrine Tumor Board. He is associate medical director of the Cancer Clinical Trials Office in Rochester, Minnesota, co-chair of the Feasibility Committee, and a member of the Clinical Research Leadership Committee. He also represents Mayo Clinic on the Neuroendocrine Tumors Guidelines Panel of the National Comprehensive Cancer Network (NCCN). Dr. Halfdanarson is the President Emeritus for the North American Neuroendocrine Tumor Society (NANETS). Julie Hallet, MD, MSc., FRCSC Surgical Oncologist Sunnybrook Health Sciences Center Panelist Dr. Hallet is an Associate Professor of Surgery at the University of Toronto and a Surgical Oncologist with a clinical practice devoted to hepato-biliary, pancreatic and upper gastrointestinal malignancies at the Odette Cancer Centre - Sunnybrook Health Sciences Centre. Her practice further focuses on neuroendocrine tumors as part of the Susan Leslie Multidisciplinary Clinic for Neuroendocrine Tumors. She completed general surgery residency and MSc in clinical epidemiology at Université Laval in Québec City, followed by a Surgical Oncology and hepato-pancreatico-biliary clinical fellowship at the University of Toronto, and additional training in advanced minimally invasive surgery at the Institut de recherche contre les cancers de l’appareil digestif (IRCAD) in Strasbourg, France. Dr. Hallet’s research focuses on health services research to improve the fidelity of care delivery in cancer surgery through patient-centred quality monitoring, high-performing team care models, and patient risk-communication support. Her work has obtained over $10 millions in peer-reviewed operating grants and led to more than 220 peer-reviewed publications. J. Randolph Hecht, MD Medical Oncologist UCLA Health Speaker/Panelist Dr. Hecht is a Professor of Clinical Medicine in the David Geffen School of Medicine at UCLA School of Medicine. He holds the Carol and Saul Rosenzweig Chair for Cancer Therapies Development and is the Director of the UCLA Gastrointestinal Oncology Program. Dr. Hecht attended medical school at Eastern Virginia Medical School. He took his internal medicine residency at Northwestern and completed fellowships in gastroenterology research at the University of Chicago, and in gastroenterology and medical oncology at UCLA. Dr. Hecht is an internationally known clinical and translational researcher in the field of gastrointestinal cancers. He has published widely on the molecular biology, early detection, and treatment of gastrointestinal malignancies. He has lead and is currently directing small trials with new molecules as well as large international randomized trials. Current ongoing research includes preclinical models of therapy with biological agents, early studies with gene therapy vectors and tyrosine kinase inhibitors, and leading phase II and phase III trials with novel agents. Andrew Hendifar, MD Medical Oncologist Cedars-Sinai Medical Center Moderator The current research focus of Andrew Hendifar, MD, is on developing new therapies for pancreatic cancer and neuroendocrine tumors. Dr. Hendifar has helped form multidisciplinary teams that specialize in the treatments of pancreatic cancer, and carcinoid and neuroendocrine tumors. Dr. Hendifar is the primary investigator for several groundbreaking therapies, including radioimmunotherapy for neuroendocrine tumors, anti-inflammatory therapy for pancreatic cancer and novel approaches to cancer cachexia. His national roles include SWOG GI Committee Member and a member of NIH Neuroendocrine Tumor Task Force. He also serves as the steering committee member for the Precision Promise Consortium and chairs the associated Supportive Care Committee. At Cedars-Sinai, he leads the Gastrointestinal Disease Research Group and is the founding Director of the Hematology and Oncology Fellowship Program. J. Gabriel Lipshutz, MD Interventional Radiologist Cedars-Sinai Medical Center Speaker/Panelist H. Gabriel Lipshutz, MD is a board-certified, fellowship-trained vascular and interventional radiologist with the Cedars-Sinai S. Mark Taper Foundation Imaging Center. Dr. Lipshutz performs all peripheral endovascular and interventional procedures including embolizations and minimally invasive oncological treatments (chemoembolization, Y-90 radioembolization, RFA, cryoablation, microwave ablation, and irreversible electroporation (IRE). His responsibilities include consultation and treatment of outpatients and inpatients, including the evaluation of patients in the IR outpatient clinic. After earning his bachelor's degree from Wesleyan University, Dr. Lipshutz earned his medical degree from the University of California, San Francisco. He completed his internship in internal medicine at the University of Washington, his radiology residency at the Oregon Health and Sciences University, and his fellowship in interventional radiology at UCLA. Dr. Heloisa Soares Medical Oncologist Huntsman Cancer Institute Speaker/Panelist Dr. Heloisa Soares is a medical oncologist who focuses on neuroendocrine cancers. She is an associate professor at the Huntsman Cancer Institute (HCI) at the University of Utah, where she is also the Medical Director for the Clinical Trials Office. Nationally, she serves as the NCI NET task force co-chair and the chair of the North American Neuroendocrine Tumor Society (NANETS) inaugural NET Patient Action Team of the NETPact Committee. She also recently served as a member of the directors for NANETS. Dr. Soares is a passionate advocate for patients. You can follow her on Twitter at @helops79.

< Back to the upcoming events page Download the Transcript Here >>> ABOUT Learn from internationally-renowned neuroendocrine cancer expert Dr. Edward Wolin in a discussion on the latest in neuroendocrine tumor treatments and understanding how to sequence them. Dr. Wolin has pioneered many of the NET treatments including somatostatin analogues (SSAs, sandostatin and octreotide), mTOR inhibitors (i.e. everolimus), anti-angiogenic drugs (i.e. cabozantinib), and peptide receptor radiotherapy (PRRT, i.e. Lutathera). Join us for an insightful presentation and live question and answer session. ABOUT DR. EDWARD WOLIN DR. Edward Wolin Professor of Medicine, Medical Oncology, Icahn School of Medicine Director, Center for Carcinoid and Neuroendocrine Tumors Tisch Cancer Institute, Mount Sinai Health System Dr. Edward M. Wolin is an internationally renowned authority on neuroendocrine tumors. Dr. Wolin is the Director of the Center for Carcinoid and Neuroendocrine Tumors at the Tisch Cancer Institute at Mount Sinai and Professor of Medicine, Medical Oncology at the Icahn School of Medicine at Mount Sinai. The multidisciplinary Center for Carcinoid and Neuroendocrine Tumors features a robust research program with clinical trials aimed at finding the most effective treatments, including immunotherapy, biologic agents, targeted radiation therapy, and new approaches in molecular imaging for diagnosis. Dr. Wolin has pioneered innovative therapies with novel somatostatin analogs, mTOR inhibitors, anti-angiogenic drugs, and peptide receptor radiotherapy. Prior to joining Mount Sinai, Dr. Wolin was Director of the Neuroendocrine Tumor Program at Montefiore Einstein Cancer Center. Previously, he worked for more than two decades with Cedars-Sinai Medical Center in Los Angeles, where he founded and directed one of the largest Carcinoid and Neuroendocrine Tumor Programs in the country, and subsequently directed the Neuroendocrine Tumor Program at University of Kentucky. Dr. Wolin is also the Co-Medical Director for the Carcinoid Cancer Foundation and is on the Carcinoid Cancer Research Grants Scientific Review Committee for the American Association for Cancer Research. He has published in many prestigious journals, including the New England Journal of Medicine and Journal of Clinical Oncology, and is a reviewer for numerous journals, including Journal of Clinical Oncology, Molecular Cancer Therapeutics, Clinical Cancer Research, and The Lancet Oncology. During Dr. Wolin’s two decades at Cedars-Sinai Medical Center in Los Angeles, he developed a close friendship with LACNETS founder Giovanna Joyce Imbesi. Dr. Wolin was instrumental in the co-founding and development of LACNETS. LACNETS has always been very dear to his heart and he cherishes and honors the memory of Giovanna. Dr. Wolin earned his medical degree from Yale School of Medicine. He completed both his residency in internal medicine and fellowship in medical oncology at Stanford University Hospital. He was also a clinical fellow at the National Cancer Institute of the National Institutes of Health. Dr. Wolin is board certified in internal medicine and medical oncology. T he opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by the Neuroendocrine Cancer Foundation or the sponsors of this program. The Neuroendocrine Cancer Foundation does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely solely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. THANKS TO OUR SPONSORS

A Study of ZL-1310 in Participants With Selected Solid Tumors << Back A Phase Ib/II, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors IDENTIFIER ( ClinicalTrials.gov ) : NCT06885281 DRUG/TREATMENT : ZL-1310 PHASE : 1/2 STATUS : Recruiting SPONSOR : Zai Lab (Shanghai) Co., Ltd. ZL-1310 in Participants With Selected Solid Tumors .pdf Download PDF • 1.98MB DESCRIPTION: This is an open-label, multi-center Phase Ib/II study testing a new targeted treatment called ZL-1310 in selected solid tumors, including gastrointestinal and pancreatic poorly differentiated neuroendocrine carcinomas (GEP NECs) and other high-grade neuroendocrine carcinomas. What is ZL-1310? ZL-1310 is a novel antibody-drug conjugate (ADC) designed to target a protein called DLL3, which is commonly found on the surface of many neuroendocrine cancers. DLL3 is considered a new and promising treatment target, especially in GEP NECs. ADCs work by combining: an antibody, which seeks out cancer cells with a specific marker (like DLL3), and a drug payload, often a chemotherapy molecule, that is delivered directly to those cells. About This Study (NCT06885281) This trial is now enrolling patients to evaluate: Safety and side effects of ZL-1310 How well the drug works in DLL3-positive neuroendocrine carcinomas How the drug behaves in the body Optimal dose levels for future studies Who Can Join (Key Inclusion Criteria) This study includes two main groups of patients: Cohort 1: People with advanced GEP NECs (including cancers of the esophagus, stomach, pancreas, gallbladder/hepatobiliary system, or colon/rectum) Must have received 1–2 prior chemotherapy or other treatment regimens Cohort 2: People with other advanced NECs or solid tumors that express DLL3 Must have received 1–2 prior treatment regimens Additional notes for patients: DLL3 testing is not required before enrolling for GEP NECs or other NECs Previous treatment with other DLL3-targeted therapies is allowed For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT: ZaiLab_1310-002_StudyTeam EMAIL: Zailab_1310-002_StudyTeam@zailaboratory.com PHONE: 86 021-61632588 This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information.

upLIFT: Ersodetug in Insulinoma/Tumor Hyperinsulinism << Back upLIFT: A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism (Tumor HI) IDENTIFIER ( ClinicalTrials.gov ) : NCT06881992 DRUG/TREATMENT : Ersodetug PHASE : 3 STATUS : Recruiting SPONSOR : Rezolute DESCRIPTION: Rezolute is a late-stage rare disease company focused on substantially improving the quality of life for individuals living with hyperinsulinism (HI) and is now enrolling participants in the upLIFT study, a phase 3 clinical trial that is testing whether or not a new therapy, called ersodetug , can safely reduce hypoglycemia in adults with tumor HI. In tumor HI, certain tumors (lumps or abnormal cell growths) in the pancreas or other parts of the body make too much insulin or a similar protein called insulin-like growth factor-2 (IGF-2). Insulinomas are a rare type of neuroendocrine tumor that usually form from the insulin-secreting cells in the pancreas. Non-islet cell tumor hypoglycemia (sometimes called “Doege-Potter syndrome” or “paraneoplastic hypoglycemia”) is a rare condition where certain tumors outside the pancreas make too much hormone growth factors that can act like insulin. Both types of tumors can lead to very low blood sugar levels, a severe and potentially life-threatening complication of overactivation of the insulin receptor. Hypoglycemia can result in neurologic and cognitive problems as well as other serious health complications and may make it hard for people with tumor HI to stay healthy enough to continue their cancer treatments. We know that patients facing these complications often have complex needs and limited treatment options. We believe collaboration between patient advocacy organizations is essential to ensure patients receive the best possible support and access to care. This study is open to people 18 and older who have a type of tumor that causes tumor HI and are still experiencing frequent, serious low blood sugar levels, even with standard treatment. To learn more about the study or potential participation please talk to your doctor or visit upliftstudy.com or clinicaltrials.gov . You may also contact patient affairs via email at patient-affairs@rezolutebio.com for further assistance, if needed. Please note that ersodetug is still under investigation and has not been approved by any health authority. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT Name: Rezolute Clinical Trial Phone Number: 650-206-4507 Email: patient-affairs@rezolutebio.com (primary contact). You may also reach out to clinicaltrials@rezolutebio.com . This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information.

CDK4/6 Abemaciclib GEP-NETS << Back Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors CLINICALTRIALS.GOV IDENTIFIER: NCT03891784 DRUG/TREATMENT: abemaciclib PHASE: 2 STATUS: Recruiting SPONSOR: University of Washington Collaborator: Eli Lilly and Company Dr. Heloisa Soares Discusses CDK4/6 abemaciclib GEP-NETS DESCRIPTION: This phase II trial studies how well abemaciclib works in treating patients with digestive system neuroendocrine tumors that have spread to other places in the body, do not respond to treatment, and cannot be removed by surgery. Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT/Principal Investigator: David B. Zhen, MD Fred Hutch/University of Washington Cancer Consortium EMAIL : dbzhen@uw.edu

CABINET: Cabozantinib in Advanced pNET and Carcinoid Tumors << Back CABINET Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients with Advanced NETs After Progression on Prior Therapy CLINICALTRIALS.GOV IDENTIFIER: NCT03375320 DRUG/TREATMENT: Cabozantinib PHASE: 3 STATUS: Closed SPONSOR: National Cancer Institute (NCI) Update - November 9, 2025 Learn about one of the biggest breakthroughs in neuroendocrine tumor (NET) treatment: the FDA approval of Cabozantinib for metastatic NETs. In this in-depth interview, the Neuroendocrine Cancer Foundation’s Lisa Yen speaks with NET expert Dr. Aman Chauhan about the landmark CABINET clinical trial, new data from ESMO 2025, and what this means for patients with pancreatic NETs, extra-pancreatic NETs, lung NETs, and thymic NETs. Clarification: The recent CABINET subgroup analysis presented at ESMO included thoracic NET patients (lung and thymic), with approximately 80% being lung NETs. Additionally, in the epNET cohort, about 20% of patients had lung NETs. Download the transcript here >>> Update - October 18, 2025 Exelixis Announces Positive Results for CABOMETYX® in Lung and Thymic Neuroendocrine Tumors At ESMO 2025, researchers reported that CABOMETYX® (cabozantinib) significantly delayed tumor growth in people with advanced lung or thymic neuroendocrine tumors—reducing the risk of disease progression or death by 81% compared to placebo. These results come from a subgroup of the phase 3 CABINET trial, which led to FDA and European approvals earlier this year for advanced pancreatic and extra-pancreatic NETs. Why this matters to patients: Lung and thymic NETs are rare and often have few treatment options. CABOMETYX offers a new targeted therapy that may help keep these tumors from growing. Read the full press release here >>> Update - March 26, 2025 A New Treatment Option has been FDA approved for those living with NET. For details, see the press release . UPDATE - September 16, 2024 On Sept 16, 2024, LACNETS interviewed incoming NANETS president, Dr. Jennifer Chan from Dana Farber Cancer Institute following her presentation on the updated, results of the CABINET trial at the medical and scientific meeting, ESMO (the European Society for Medical Oncology) Congress 2024 in Barcelona, Spain. The presentation was titled Cabozantinib Versus Placebo for Advanced Neuroendocrine Tumors (NET) after Progression on Prior Therapy (CABINET Trial/Alliance A021602): Updated Results Including Progression Free-Survival (PFS) by Blinded Independent Central Review (BICR) and Subgroup Analyses. Watch our latest interview on Sept 16, 2024 with Dr. Jennifer Chan at ESMO (the European Society for Medical Oncology) Congress 2024 in Barcelona, Spain. For more information, read our blogpost: Positive Results of the Cabinet Trial Show Cabozantinib As a New Effective Treatment in Advanced Neuroendocrine Tumors . Read more in the latest NEJM article released Sept 16, 2024: Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. UPDATE - October 25, 2023 Dr. Jennifer Chan from Dana Farber Cancer Institute shared the CABINET trial data that showed cabozantinib (CABOMETYX®) helped those with advanced pancreatic NET and extra pancreatic NET (NET outside the pancreas). The results suggest that cabozantinib may be an effective option to treat NET patients, even those who have already tried other therapies. The NET patient community can be hopeful that there will likely be another FDA-approved oral treatment available in the near future. Click here to read the detailed results of the CABINET trial here: Business Wire - "Detailed Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023 " OncLive - "Cabozantinib Confers PFS Benefit in Previously Treated Advanced Neuroendocrine Tumors" Watch this exclusive video interview with Dr. Jennifer Chan at ESMO - European Society for Medical Oncology 2023 in Madrid, Spain. UPDATE - Aug 24, 2023 The Alliance for Clinical Trials in Oncology announced that the CABINET trial (NCT03375320) showed positive findings with cabozantinib having efficacy. The CABINET trial is a phase 3 randomized, double-blinded study evaluating cabozantinib compared with placebo in patients with advanced pancreatic neuroendocrine tumors (PNET) or advanced extra-pancreatic neuroendocrine tumors (carcinoid tumors) who experienced progression after prior systemic therapy. The trial is now being stopped early. It will be unblinded, meaning the patients will find out if they have been receiving placebo and those who have will have the possibility of receiving cabozantinib. The findings will be discussed with the U.S. Food and Drug Administration. Detailed results from the trial will be presented at an upcoming scientific meeting. To read the announcement, go to https://bit.ly/A021602-Interim or https://www.onclive.com/view/cabozantinib-efficacy-prompts-cabinet-trial-unblinding-in-advanced-pancreatic-and-extra-pancreatic-nets. Dr. Jennifer Chan Discusses CABINET: Cabozantinib DESCRIPTION: This phase III trial studies cabozantinib to see how well it works compared with placebo in treating patients with neuroendocrine or carcinoid tumors that have spread to other places in the body (advanced). Cabozantinib is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors that, when blocked, may slow tumor growth. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. PRINCIPAL INVESTIGATOR: Jennifer A Chan, MD, MPH Alliance for Clinical Trials in Oncology and National Cancer Institute (NCI)

Belzutifan/MK-6482 in PNET + PPGL + VHL << Back Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015) CLINICALTRIALS.GOV IDENTIFIER: NCT04924075 DRUG/TREATMENT: Oral Treatment: Belzutifan PHASE: 2 STATUS: Recruiting SPONSOR: Merck Sharp & Dohme LLC Update (May 14, 2025): Based on results from this study, the FDA approved belzutifan (Welireg) for patients with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL). This is the first oral therapy approved for PPGL and represents an important new treatment option. Read the FDA announcement → Dr. Hendifar Discusses Belzutifan in PNET + PPGL + VHL DESCRIPTION: Merck is sponsoring a phase 2 trial for those with pheochromocytoma/paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET), or Von Hippel-Lindau (VHL) who have progressed in the past 12 months. Those with pNET must have experienced disease progression on or after at least 1 line of prior systemic therapy that includes an approved targeted agent such as everolimus or sunitinib. Belzutifan is a daily, oral medication currently approved for the treatment of von Hippel–Lindau disease-associated renal cell carcinoma. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT: Merck Sharp & Dohme LLC EMAIL: Trialsites@merck.com PHONE: 1-888-577-8839 This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information.

<< Go back to the Podcast page EPISODE 49 - Understanding Carcinoid Syndrome & GLP-1 Drugs in Neuroendocrine Tumors Download a Transcript of this Episode >>> ABOUT THIS EPISODE Carcinoid syndrome can be confusing and often difficult to diagnose. In this episode, Dr. Joseph Dillon , Endocrinologist and Director of the University of Iowa Neuroendocrine Multidisciplinary Tumor Clinic, explains what carcinoid syndrome is, how it’s diagnosed, and the various ways it can be treated. He highlights key symptoms, testing, and treatment approaches—including somatostatin analogs and telotristat—and discusses how to distinguish carcinoid syndrome from other causes of diarrhea and flushing. In the second half of the episode, Dr. Dillon shares insights from his separate line of research on GLP-1 receptor agonist weight-loss drugs (such as Ozempic® and Mounjaro®) and their potential implications for neuroendocrine tumor patients. (Note: this topic is unrelated to carcinoid syndrome.) MEET DR. JOSEPH DILLON Dr. Dillon is a Professor of Medicine in the Division of Endocrinology at the University of Iowa Hospitals and Clinics. He directs the University of Iowa Neuroendocrine Multidisciplinary Tumor Clinic. This was the first and only US NET Clinic to be recognized as a Center of Excellence by the European NET Society. He is also the Director of the PheoPara Alliance Center of Excellence at University of Iowa. His clinical practice is entirely focused on the care of people with neuroendocrine tumors, both carcinoid type and paraganglioma. He has participated in clinical trials and publications related to diagnostic and therapeutic nuclear agents and drug therapies in this population. Prior to focusing on NET he made important discoveries in the field of GLP-1 which are now becoming of importance to NET patients taking popular weight loss drugs. TOP TEN QUESTIONS: What is carcinoid syndrome? Who is affected by carcinoid syndrome? How does someone know if they have carcinoid syndrome? 3.What are the tests for carcinoid syndrome? How is carcinoid syndrome distinguished from other causes of my symptoms? *Could the tests be negative but someone still have carcinoid syndrome? Can someone have no evidence of neuroendocrine tumors and still have carcinoid syndrome? For those who have carcinoid syndrome, what additional tests should they have? Why should carcinoid syndrome be treated? What are the possible issues if it is not treated? How is carcinoid syndrome treated? *What is on the horizon for carcinoid syndrome treatment? Can carcinoid syndrome be prevented or detected early? Is there anything people can do to prevent or lessen carcinoid syndrome symptoms? Are there any factors that worsen carcinoid syndrome such as age, weight or other diseases? You recently published a study discussing possible risks of using certain weight loss drugs in people with neuroendocrine cancer. Could you tell us more about this study? What was the drug and what did you find? What does it mean? What do you want the NET patient community to understand about your recent findings? RESOURCES WATCH Educational Videos on Diarrhea Watch Dr. Dillon’s video (3:41min) - " How Do GLP-1 Agents Factor Into Neuroendocrine Tumor Care Strategies?" (Nov 5, 2025) LISTEN EXPLORE Carcinoid Heart Disease Resources Somatostatin Analogue (SSA) Resources Xermelo Resources Paltusotine in Carcinoid Syndrome Clinical Trial READ Shilyansky J. et al. (2025). " GLP-1R agonist promotes proliferation of neuroendocrine neoplasm cells expressing GLP-1 receptors " Download Article >>> DISCLAIMER The Neuroendocrine Cancer Foundation Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of the Neuroendocrine Cancer Foundation. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS